H.C. Wainwright lowered the firm’s price target on ADC Therapeutics to $3 from $12 and keeps a Buy rating on the shares post the Q3 report. The analyst says Zynlonta quarterly sales fell on a sequential basis. The firm reduced peak penetration rates for Zynlonta in the second line and third line settings to 10% and 20% from the prior 25% and 25%, respectively.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ADCT:
- ADC Therapeutics downgraded at TD Cowen on lack of Zynlonta growth
- ADC Therapeutics downgraded to Market Perform from Outperform at TD Cowen
- ADC Therapeutics receives NYSE notice of non-compliance
- ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
- ADC Therapeutics expects cash runway to extend into middle of 2025